Announcements Trials
Browse Landscape

Phase

Phase 2 36Phase 1 26Phase 1/2 15Phase 3 6Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Esophageal Squamous Cell Carcinoma 6Leukemia 5Esophageal Neoplasms 5Rectal Neoplasms 3Lymphoma 3Head and Neck Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Prostatic Neoplasms 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Oropharyngeal Neoplasms 2Oligodendroglioma 2Nasopharyngeal Carcinoma 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, T-Cell 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Carcinoma 2Astrocytoma 2Anemia, Refractory, with Excess of Blasts 2Adenocarcinoma Of Esophagus 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

Temozolomide 2veliparib 1Radiotherapy 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Contrast Media 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Gliosarcoma × Radiotherapy × Clear all
NCT04396860 2026-04-22

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

National Cancer Institute (NCI)

Phase 2/3 Completed
159 enrolled 17 charts
Sarcoma

Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡